Break-up submitted for Vitamin A and Vitamin C

3529. SHRI BHUBANESWAR KALITA: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 1897 given in the Rajya Sabha on the 14th March, 1988 and state:

(a) whether it is a fact that the increase in material cost and other heads is insignificant in comparison to the costs taken in the break up by the producers of Vitamin A and Vitamin C;

(b) if so, what was the break up submitted by each of the producers when these drugs were under price control and what break up was accepted by BICP and his Ministry;

(c) under which heads such high increase has been taken in the present break up;

(d) whether his Ministry has examined the break up;

(e) if so, what is the justification;

(f) if not, by when his Ministry will examine;

(g) whether his Ministry has decided to control the prices of these drugs; and

(h) if so, by when?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (c) Reasons for increase in prices vary from case to case. In general increase in due to increase in the cost of raw material, bonus, interest, profit margin etc.

(d) to (h) At the intervention of the Government the producers of Vitamin A & C have reduced their prices as follows:

	Previous Price (Rs.)	Current Price (Rs.)
(1) Vitamin A Acetate Dry Powder (0.5 MIU/gm) 1000 MIU	2400.00 Roche 2600.00 KSDPL	2100.00
(2) Vitamin A Palmitate (1.0 MIU/gm) 1000 MIU	1500.00 Roche & KSDPL	1300.00 Roche & KSDPL
(3) Vitamin A Palmitate (1.7 MIU/gm) 1000 MIU	1500.00 Roche	1300.00 Roche
(4) Vitamin C Kg.	320.00 Sarabhai M.Chemicals	240.00 Sarabhai M. Chemicals

Exemption of small scale drug units from price control

3530. SHRIMATI SUDHA VIJAY JOSHI: Will the Minister of INDUSTRY be pleased to state;

(a) whether it is a fact that there are a number of small scale drug units having turn-over between 25 crores to 100 crores;

(b) if so, what are the names of such units;

(c) whether it is also a fact that these units are exempted from price control of finished medicines based on Category II drugs;

(d) whether it is also a fact that most of these units have monopoly production of certain finished medicines and have dominance; and

(e) if so, the names of Category II drugs, the names of their finished medicines along with the names of small scale units which enjoy monopoly along with the market share of each?